Physician profile
Munir Shah
NPI 1437240611
$8,312.63
in general payments reported to CMS, 2019-2025
21 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,041 · 2020: $2,782 · 2021: $233 · 2022: $181 · 2023: $188 · 2024: $399 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.58 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,203.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $411.92 | 2019-2025 | Zerbaxa |
| Abbvie INC. | $389.68 | 2021-2025 | Teflaro |
| Gilead Sciences, INC. | $341.17 | 2019-2024 | Epclusa |
| Inspire Medical Systems, INC. | $142.05 | 2025 | Inspire |
| Viiv Healthcare Company | $137.96 | 2024 | Dovato |
| Tetraphase Pharmaceuticals, INC. | $136.41 | 2019-2020 | |
| Glaxosmithkline, LLC. | $134.64 | 2020-2024 | Arexvy |
| Amarin Pharma, INC. | $101.57 | 2020 | |
| Novo Nordisk INC | $56.82 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.65 | 2025 | Cuvitru |
| La Jolla Pharmaceutical Company | $39.58 | 2021-2022 | |
| Melinta Therapeutics, LLC | $36.11 | 2019-2021 | |
| Boston Scientific Corporation | $30.43 | 2023 | Watchman Access System, Rezum Generator |
| Xeris Pharmaceuticals, INC. | $18.37 | 2024 | Recorlev |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $17.46 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.38 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.01 | 2021 | |
| Recordati_rare_diseases_inc. | $13.70 | 2025 | Isturisa |
| Shionogi INC | $12.04 | 2022 | |
| Beta Bionics, INC. | $10.24 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munir Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.